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Conclusions: This meta-analysis demonstrates Level-II 
evidence of the high diagnostic performance of MRI in staging 
hilar/mediastinal LNs in NSCLC on both per-patient and per-
nodal basis. Relative to FDG-PET/CT, pulmonary MRI is able 
to reach higher sensitivity at similar specificity, encouraging 
future prospective studies on treatment decision-making and 
selective nodal irradiation in NSCLC. However, before 
pulmonary MRI can replace FDG-PET/CT in NSCLC 
radiotherapy, thorough assessment of geometric distortion in 
MR images is mandatory. 
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Purpose/Objective: The advantage of proton therapy is the 
presence of a sharp distal dose fall-off that can be used to 
spare normal tissues beyond the end of the delivered field. 
However, due to this sharp fall-off, even small errors 
resulting from patient misalignments could potentially result 
in a significant discrepancy between the planned and the 
delivered dose. Therefore, to tap the full potential of proton 
therapy, accurate and on-line methods to verify the patient 
positioning and the proton range during the treatment are 
desirable. Here we propose and validate a fast and innovative 
technique for determining shift and rotational positional 
uncertainties for proton therapy using what we call 'range 
probes'. A range probe is a narrow, high energy proton pencil 
beam that shoots through the patient and can be detected on 
exit and for which the residual range and shape of the Bragg 
peaks (BP) can be measured using a multi-layer-ionisation-
chamber (MLIC) (see Figure 1). By the use of a number of 
carefully selected range probe positions, the ranges of the 
detected BP's can uniquely define the orientation of the 
patient. 
Materials and Methods: To validate this approach, an 
anthropomorphic phantom has been used, and a planning CT 
acquired. From this, 700 new CT's were generated, assuming 
different rotations along each axis. Five low dose range 
probes with energy 177 MeV were then simulated to pass 
through all these CT data sets using the VMCPro Monte Carlo 
code, with the residual BP's of each range probe being stored 
in a database to which experimentally measured range probe 
BP's can be compared. The phantom was then placed on a 
rotation device and three new CT's with randomly generated 
rotations were acquired, representing three possible daily 
positioning's of the patient. To determine these 'daily' 
rotational positioning errors, range probes were simulated 
through these 'daily' CT data sets, and the results compared 
to the pre-calculated data base, from which the actual 'daily' 
rotational error could be determined. 
 
 
 
Results: In Table 1 the comparison between the predicted 
rotations and the daily errors are reported for the three 
studied cases. The calculation performed shows that a 
rotational positioning errors of the phantom can be detected 
with a resolution of about derror=1°. 
 
 
 
Conclusions: With this phantom study we have demonstrated 
the possible use of a small number of proton range probes for 
detecting on-line, residual rotational misalignments of 
patients with a high level of accuracy. The technique is fast 
and can effectively reconstruct three-dimensional positioning 
errors from a single proton beam angle. 
Even if further investigations and measurements are required 
before the method can be applied in clinical routine, our 
simulations and measurements have shown the feasibility of 
the approach. 
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Purpose/Objective: To report the clinical results of a five 
years experience in the neo-adjuvant treatment of rectal 
cancer within a moderate hypofractionated regimen (18 
